BIOADAPTIVES INC - BDPT STOCK NEWS

BioAdaptives, Inc. (OTCMkts: BDPT) has acquired U.S. Patent 9,783,432B from inventor Thomas J. Mohr to enhance oxygen capacity in water. This technology embeds oxygen molecules, offering long-term aerobic benefits for performance and health. The company is forming MORO2, Inc. to develop consumer products based on this technology, with marketing set to begin in 2Q 2022. Under the agreement, BioAdaptives holds exclusive rights for two years and has engaged Mohr as a consultant. This acquisition positions the company for growth in nutraceutical-enhanced oxygenated water products.

BioAdaptives, Inc. (OTCMkts: BDPT) has initiated a study of its Lung Armor™ package, which includes the Lung Cleanser™ device and PrimiLungs™ supplement, targeting respiratory health in long-term smokers and those exposed to second-hand smoke. The Lung Cleanser™ is an FDA-cleared medical device aimed at enhancing lung clearance. Research will evaluate user experience and potential improvements in product efficacy, with initial studies planned in the US and possibly Eastern Europe. The company seeks to provide daily support for smokers’ breathing and health through its innovative products.

BioAdaptives (OTCMkts: BDPT) announced a Letter of Intent to acquire U.S. Patent 9,783,432B from inventor Thomas J. Mohr. This patent covers a revolutionary technology that enhances water's ability to retain oxygen, providing longer-term health benefits compared to traditional oxygenated water. CEO Edward Jacobs emphasized the potential advantages of the new product, which may improve endurance and overall wellness. While the financial terms are still being negotiated, the deal involves cash, royalties, and warrants. BioAdaptives aims to expand its product line with this innovative technology.

BioAdaptives (OTC: BDPT) has entered a Marketing Agreement with Acoustic Innovations LLC for the LungFlute™ device, which is FDA-cleared and supports lung health and diagnosis of pulmonary diseases. The agreement grants BioAdaptives marketing rights across the US, Canada, and other approved regions. The LungFlute™ aids in mucus clearance and is expected to enhance TB diagnosis in an $800,000 trial in Africa. BioAdaptives plans to promote the device alongside its PrimiLungs™ supplement in a new package called LungArmor™ aimed at improving lung hygiene and immune defense.

BioAdaptives, Inc. (OTCMkts: BDPT) announces a collaboration with Professor Lorrin Koran from Stanford Medical Center for research on PluriPain®, aimed at alleviating chronic pain linked to Gadolinium Deposition Disease. This rare disorder surfaces in patients exposed to gadolinium from MRI contrast agents, resulting in prolonged pain through inflammatory cytokine production. BioAdaptives will supply PluriPain® for this research, furthering its commitment to addressing inflammatory pain issues.

BioAdaptives (OTCMkts: BDPT) announced the launch of its Ambassador Program for the Livestock Impact Division, promoting products like Equine All-in-One™ and Canine Regen®. The program aims to enhance affiliate marketing through social media and discounts, targeting industry participants. Notably, Equine All-in-One™ is a plant-based supplement reported to improve horse health and performance, while Canine Regen® supports dog health and regeneration. The initiative will be led by COO Charles Townsend, with plans for national and potential international outreach.

BioAdaptives, Inc. (OTCMkts: BDPT) has entered a Licensing and Co-Marketing Agreement with The Fedr8tion Ltd., which has 11 million affiliate members. This partnership allows BioAdaptives to offer special membership pricing on its nutraceuticals through Fedr8tion’s platform, enhancing its reach to a new demographic within the e-gaming community. The collaboration aims to introduce BioAdaptives' natural supplement products to a younger audience engaged in e-sports, leveraging Fedr8tion's established member base and marketing capabilities.

BioAdaptives, Inc. (OTCMkts: BDPT) announces key executive appointments: Charles Townsend is appointed Chief Operating Officer and director, Robert W. Ellis remains President and becomes a director, and Ronald Lambrecht is reappointed Chief Financial Officer. Townsend brings over 30 years of experience from various sectors, including operations and enterprise marketing, enhancing the leadership team's strength. The company focuses on natural health products for humans and animals, emphasizing wellness and innovative formulations.

BioAdaptives, Inc. (OTCMkts: BDPT) has launched a new social media advertising campaign aimed at promoting its pain relief and immune-boosting products. Partnering with J Ramsdell Consulting and The Dropup Agency, the company will utilize targeted marketing through Click Funnels and social platforms like Facebook, Instagram, and YouTube. CEO Edward Jacobs highlighted years of research leading to advanced formulations, anticipating significant revenue growth from this initiative. The company manufactures natural health products, emphasizing pain relief and immune defense, with a commitment to holistic wellness.